MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium ProgramShimin Hu, Ken H. Young, Zijun Y. Xu‐Monette et al.|Blood|2013Cited by 677
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell LymphomaMark W. Clemens, Roberto N. Miranda, L. Jeffrey Medeiros et al.|Journal of Clinical Oncology|2015Cited by 418
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program StudyZijun Y. Xu‐Monette, Ken H. Young, Govind Bhagat et al.|Blood|2012Cited by 390
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program StudyShimin Hu, Ken H. Young, Zijun Y. Xu‐Monette et al.|Blood|2013Cited by 246
Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of MelanomaWesley O. Greaves, Rajyalakshmi Luthra, Shalini Verma et al.|Journal of Molecular Diagnostics|2012Cited by 217